StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project：[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
Zurück
HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 6000Erstellt: 1. November 2026

Tubocurarine

Jexin · Aids002682 · Aids-002682 · DELTA-TUBOCURARINE · 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium · 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium · (+)-7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium · 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido[3',2':14,15][1,11]dioxacycloeicosino[2,3,4-ij]isoquinolinium,2,3,13a,14,15,16,25,25a-octahydro-9,19-dihydroxy-18,29-dimethoxy-1,14,14-trimethyl-,(13aR,25aS)-

https://huagongshe.com/de/chemical/6000

Molekülstruktur von Tubocurarine

Identifikatoren & physikalische Daten

CAS No.57-95-4
SummenformelC37H41N2O6+
Durchschnittliche Molmasse609,7 g/mol
Monoisotopische Masse609,29646203 g/mol
SMILESCOc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C
InChIKeyJFJZZMVDLULRGK-URLMMPGGSA-O
PubChem CID6000
ChEMBLCHEMBL339427
ChEBICHEBI:9774
EC No.886-985-5
DTXSIDDTXSID0048393

Chemische & physikalische Eigenschaften

XLogP6
Polarare Oberfläche (TPSA)80,6
H-Brücken-Donoren2
H-Brücken-Akzeptoren7
Frei drehbare Bindungen2
Schwere Atome45
Formalladung1
Komplexität990
ArzneimittelPharmaceuticals -> Listed in ZINC15
LöslichkeitSolublity (25 °C): approx 50 mg/l waterbut supersaturated solustions are formed readily. Solubility also reported as approximately 1 g/40 ml waterapproximately 1 g/75 ml ethanol. Also soluble in methanol. Insoluble in pyridine, chloroform, benzene, acetone, ether. /Chloride, d-Form/Crystals, dec about 236 °C (effervescence)specific optical rotation: +185 deg @ 25 °C/Dto +195 °C (c=0.5 in H2O), UV max (acidified 0.005% aq soln): 280 nm (A= ~89, 1%, 1 cm). Soluble in water, dil sodium hydroxide, Sparingly sol in alcohol, in dil HCl, chlorform. Practically insoluble in benzene, ether. /Dimethyl ether/INSOL IN DIETHYL ETHER /CHLORIDE/3.23e-04 g/L
DecompositionWhen heated to decomposition it emits toxic fumes of nitroxides.
SchmelzpunktNeedles from watermp: 268 °C (effervescence)specific optical rotation: -258 deg @ 20 °C (c=0.38) for the anhydrous salt /Chloride, l-Form/
Optical RotationHexagonal and pentagonal microplatelets from water. Can exist in the form of various hydrates. The anhydrous materl (dec 274-275 °C) takes up water in moist atm until it reaches the pentahydrate stage, dec approximately 270 °C. Specific optical rotation: +190 deg @ 22 °C/D+219 deg @ 23 °C/D (c= 0.785 in methanol). UV max (H2O): 280 nm (E=118, 1%, 1 cm). /Chloride, d-Form/
Physical DescriptionSolid
Stability/Shelf LifeSENSITIVE TO LIGHT /CHLORIDE/
Collision Cross Section236 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]235.15 Ų [M]+ [CCS Type: TW
Other Experimental PropertiesWhite to light-tan crystalline alkaloidodorless. MP 270 °C with decomposition. Soluble in water and alcoholinsoluble in acetone, chloroform, and etheraqueous solution is strongly dextrorotary (specific rotation for 1% solution of anhydrous -208 to +218 degrees). /Chloride/ODORLESS, WHITE, YELLOWISH WHITE TO GRAYISH WHITE CRYSTALLINE POWDER /CHLORIDE/ODORLESS, WHITE OR PALE YELLOW CRYSTALLINE POWDER /DIMETHYL IODIDE/CRYSTALSMAX ABSORPTION: 280 NM (E= 74, 1%, 1CM)SOL IN WATER APPROX 300 MG/100 MLSLIGHTLY SOL IN DIL HYDROCHLORIC ACID, DIL SODIUM HYDROXIDEVERY SLIGHTLY SOL IN ALCPRACTICALLY INSOL IN BENZENE, ETHER, CHLOROFORMSPECIFIC OPTICAL ROTATION: +148 TO +158 DEG @ 22 °C/D (0.25%) /DIMETHYL IODIDE/SPECIFIC OPTICAL ROTATION: +190 DEG @ 22 °C/D (0.5%)+219 DEG @ 23 °C/D (METHANOL, 0.785%)DECOMP APPROX 270 °C /PENTAHYDRATE, CHLORIDE/
Siedepunkt663.91°C (rough estimate)
Dichte1.1423 (rough estimate)
Brechungsindex1.5300 (estimate)
EPA chemische InformationenTubocurarine (57-95-4)

Sicherheit & Vorschriften

FDA-AnforderungenManufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392).
LagerbedingungenStore ... at controlled room temperature. ... Freezing should be avoided. /Tubocurarine chloride/
EntsorgungsverfahrenSRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
TreatmentIf the compound has been ingested, rapid gastric lavage should be performed using 5% sodium bicarbonate. For skin contact, the skin should be washed with soap and water. If the compound has entered the eyes, they should be washed with large quantities of isotonic saline or water. In serious cases, atropine and/or pralidoxime should be administered. Anti-cholinergic drugs work to counteract the effects of excess acetylcholine and reactivate AChE. Atropine can be used as an antidote in conjunction with pralidoxime or other pyridinium oximes (such as trimedoxime or obidoxime), though the use of '-oximes' has been found to be of no benefit, or possibly harmful, in at least two meta-analyses. Atropine is a muscarinic antagonist, and thus blocks the action of acetylcholine peripherally.
WechselwirkungenEPINEPHRINE & NOREPINEPHRINE EXERT ANTICURARE EFFECT, PROBABLY BY INCR AMT OF ACH /ACETHYLCHOLINE/ RELEASED @ NERVE TERMINAL. /NEUROMUSCULAR BLOCKING AGENTS/NEUROMUSCULAR BLOCKING EFFECT OF TUBOCURARINE CAN BE ANTAGONIZED...BY... NEOSTIGMINE METHYLSULFATE OR...PYRIDOSTIGMINE...WITH ATROPINE.../&/ EDROPHONIUM CHLORIDE...HAS VERY BRIEF DURATION OF ACTION...MANY ANTIBIOTICS (EG, STREPTOMYCIN, NEOMYCIN, POLYMYXIN B, COLISTIN, KANAMYCIN, BACITRACIN, GENTAMICIN, AMIKACIN, LINCOMYCIN, CLINDAMYCIN) ENHANCE THE NEUROMUSCULAR BLOCK PRODUCED BY TUBOCURARINE ... QUINIDINE, MAGNESIUM SULFATE, AND TRIMETHAPHAN (BUT NOT SODIUM NITROPRUSSIDE) ALSO HAVE BEEN REPORTED TO POTENTIATE THE NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE.MISCELLANEOUS DRUGS THAT MAY HAVE SIGNIFICANT INTERACTIONS WITH ... COMPETITIVE ... NEUROMUSCULAR BLOCKING AGENTS INCL TRIMETHAPHAN, OPIOID ANALGESICS, PROCAINE, LIDOCAINE, QUINIDINE, PHENELZINE, PHENYTOIN, PROPANOLOL, MAGNESIUM SALTS, CORTICOSTEROIDS, DIGITALIS GLYCOSIDES, CHLOROQUINE, CATECHOLAMINES, AND DIURETICS. /NEUROMUSCULAR BLOCKING AGENTS/

Anwendungen & Verwendung

Verwenden

Neuromuscular blocking agent.

For more Interactions (Complete) data for TUBOCURARINE (19 total), please visit the HSDB record page.
Gesundheitliche AuswirkungenAcute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Certain reproductive effects in fertility, growth, and development for males and females have been linked specifically to organophosphate pesticide exposure. Most of the research on reproductive effects has been conducted on farmers working with pesticides and insecticdes in rural areas. In females menstrual cycle disturbances, longer pregnancies, spontaneous abortions, stillbirths, and some developmental effects in offspring have been linked to organophosphate pesticide exposure. Prenatal exposure has been linked to impaired fetal growth and development. Neurotoxic effects have also been linked to poisoning with OP pesticides causing four neurotoxic effects in humans: cholinergic syndrome, intermediate syndrome, organophosphate-induced delayed polyneuropathy (OPIDP), and chronic organophosphate-induced neuropsychiatric disorder (COPIND). These syndromes result after acute and chronic exposure to OP pesticides.
ExpositionspfadeInjection (sting/bite) (L1256)
ToxizitätsübersichtTubocurarine is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a halide or thiocyanate), and a terminal oxygen.
Signs and SymptomsCurare is a muscle relaxant and thus causes paraylsis. (L1256)
Human Toxicity ExcerptsLarge doses and overdoses may cause respiratory paralysis and hypotension.Inadvertent intraarterial injection of tubocurarine in the left antecubital fossa results in pain and weakness of the extremity. /Tubocurarine chloride/
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Non-Human Toxicity ExcerptsANIMALS POISONED BY D-TUBOCURARINE ... 1ST EXHIBIT MOTOR WEAKNESS, & ULTIMATELY MUSCLES BECOME TOTALLY FLACCID & INEXCITABLE ... MUSCLES ... OF FINGERS, TOES, EYES, & EARS ARE INVOLVED BEFORE THOSE OF LIMBS, NECK, & TRUNK. ULTIMATELY INTERCOSTAL MUSCLES & FINALLY DIAPHRAGM ARE PARALYZED, & RESP THEN CEASES.DEATH /IN ANIMALS POISONED BY D-TUBOCURARINE/ IS CAUSED BY HYPOXIA SECONDARY TO PERIPHERAL RESPIRATORY PARALYSIS. TERMINAL ASPHYXIAL CONVULSIONS MAY APPEAR, BUT THESE ARE MILD OWING TO ALMOST COMPLETE MUSCULAR PARALYSIS.SALIVATION, RETCHING, DEFECATION, BRONCHOSPASM, & INTESTINAL HEMORRHAGE REPORTED IN DOGS ARE PROBABLY IN PART ASSOC WITH.../D-TUBOCURARINE'S/ HISTAMINE RELEASE. /CHLORIDE/HYPOTHERMIA ANTAGONIZES D-TUBOCURARINE-INDUCED NEUROMUSCULAR BLOCKADE BUT DECR ELIMINATION. AT 28 DEGREE NET EFFECT IS PROLONGATION OF NEUROMUSCULAR BLOCKADE.For more Non-Human Toxicity Excerpts (Complete) data for TUBOCURARINE (7 total), please visit the HSDB record page.
Non-Human Toxicity ValuesLD50 Rat ip 210 ug/kgLD50 Rat im 500 ug/kgLD50 Mouse ip 410 ug/kgLD50 Mouse sc 560 ug/kgFor more Non-Human Toxicity Values (Complete) data for TUBOCURARINE (9 total), please visit the HSDB record page.
Gefahrstoffdaten57-95-4(Hazardous Substances Data)